ribociclib,palbociclib
novartis,pfizer
['bcsm', 'ribociclib', 'palbociclib']
maintain: randomized phase ii, ribociclib vs placebo together with new endocrine partner after progression on endocrine therapy + cdk4/6i (mostly palbociclib). improved pfs. response rate 20% vs 11%, not statistically significant. #asco22 #bcsm 
Medical oncologist @Intermountain, Director of Breast Oncology. Clinical research, quality improvement, cardio-oncology, provider wellness. All tweets my own.